Antiretroviral Therapy and Efficacy After Virologic Failure on First-line Boosted Protease Inhibitor Regimens | Zendy

Yu Zheng | Zendy; Michael D. Hughes | Zendy; Shahin Lockman | Zendy; Constance A. Benson | Zendy; Mina C. Hosseinipour | Zendy; Thomas Campbell | Zendy; Roy M. Gulick | Zendy; Eric S. Daar | Zendy; Paul E. Sax | Zendy; Sharon A. Riddler | Zendy; Richard Haubrich | Zendy; Robert A. Salata | Zendy; Judith S. Currier | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antiretroviral Therapy and Efficacy After Virologic Failure on First-line Boosted Protease Inhibitor Regimens

Author(s) -

Yu Zheng,

Michael D. Hughes,

Shahin Lockman,

Constance A. Benson,

Mina C. Hosseinipour,

Thomas Campbell,

Roy M. Gulick,

Eric S. Daar,

Paul E. Sax,

Sharon A. Riddler,

Richard Haubrich,

Robert A. Salata,

Judith S. Currier

Publication year - 2014

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciu367

Subject(s) - regimen , medicine , ritonavir , protease inhibitor (pharmacology) , reverse transcriptase inhibitor , odds ratio , confidence interval , viral load , gastroenterology , immunology , virus , antiretroviral therapy

Virologic failure (VF) on a first-line ritonavir-boosted protease inhibitor (PI/r) regimen is associated with low rates of resistance, but optimal management after failure is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research